Drug company marketing scandals have often made headlines. However, in recent years, a raft of new pharmaceutical industry transgressions has created crises for health care systems of high-income countries as well as poorer nations. Prices of life-saving drugs are soaring; supply shortfalls of essential medications have become common; development of new antibiotics against resistant organisms is lagging; and inequalities in access to medicines are widening. Policymakers must find new solutions to protect health systems and health.
GaffneyA. Healing an ailing pharmaceutical system: Prescription for reform for United States and Canada. Br Med J.2018;361:k1039. Available from: 10.1136/bmj.k1039. Accessed January 17, 2023
SchröderMTelschowC. Entwicklung der Arzneimittelkosten und -preise in der Versorgung (page .67). In: SchröderHHelmut, ThürmannPTelschowCSchröderMBusseR, eds. Arzneimittel-Kompass 2021. Hochpreisige Arzneimittel - Herausforderung und Perspektiven. Springer-Verlag; 2021: 65–78.
Denknetz-Arbeitsgruppe Big Pharma. Toxic Pharma: Warum toxisch hohe Preise für Medikamente dringend eliminiert werden müssen, und warum es im Pharmabereich und der medizinischen Forschung einen starken, global vernetzten Service public braucht. Available from: https://www.denknetz.ch/wp-content/uploads/2017/07/toxic_pharma_12.12.16_def.pdf. Accessed January 17, 2023
11.
ClearyEBeierleinJKhanujaNMacNameeLLedleyF. Contribution of NIH funding to new drug approvals 2010-2016, in: PNAS. Proceedings of the National Academy of Sciences of the United States of America, March 6, 2018, 2329-2334. Available from: 10.1073/pnas.1715368115. Accessed January 18, 2023.
12.
AngellM. Der Pharma-Bluff. Wie innovativ die Pillenindustrie wirklich ist. KomPart Verlagsgesellschaft, Bonn / Bad Homburg, 2005. page 34f.
